New model aims to perfect antibiotic dosing for sepsis in the ICU

NCT ID NCT03748095

Completed Knowledge-focused Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This study looked at 91 sepsis patients in intensive care to create a computer model that predicts the right dose of the antibiotic piperacillin/tazobactam. Researchers took blood samples at different times to measure drug levels. The goal was to develop a tool that helps doctors give the most effective and safe dose for each patient, reducing the risk of underdosing or side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: piperacillin/tazobactam (an antibiotic combination)
What this could lead to: If successful, this could lead to more personalized antibiotic dosing for sepsis patients in intensive care, potentially improving outcomes and reducing side effects.
What could go wrong: This is a small, completed modeling study, not a treatment trial. The model needs further validation before it can be used in practice, and results may not apply to all sepsis patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESUSCITATION PATIENTS WITH SEPSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESUSCITATION PATIENTS WITH SEPSIS

Contacts and locations

Locations

CHU de Rouen

Rouen, France, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.